Skip to main content

MS news

Our news web pages include ground-breaking multiple sclerosis news and research from around the world. 

These news stories are taken from external sources and as such, MS-UK does not verify, endorse or accept responsibility for their content.

Some of these pages have been written for medical professionals and this can be reflected in the complexity of language and content. If you have any issues relating to the topics here, please call the MS-UK Helpline on 0800 7830 518.


 

A virus known to cause respiratory infections in people — the human coronavirus (HCoV) — may also be the source of neurological diseases that affect people, a new study reported.

Results...

In the appraisal consultation document published on the NICE website, the appraisal committee's preliminary recommendation states:

Daclizumab is not recommended within its marketing...

Exposure to heavy metals and being female are associated with a higher incidence of multiple sclerosis, according to a study conducted by Maria Cristina Monti and colleagues from two Italian...

Some researchers have theorised that regular physical activity reduces the risk of developing multiple sclerosis. A new analysis demonstrates that, as a preventative measure, exercise does not...

In its effort to end progressive multiple sclerosis the International Progressive MS Alliance (PMSA) has awarded a $6.1 million grant to fund a research project led by Dr. Douglas Arnold with the...

Testing blood samples for levels of neurofilament light chains (NfLs) can identify patients with multiple sclerosis, as well as indicate degree of disease activity, new research suggests.

...

A new Tel Aviv University study published in the Journal of the American Chemical Society (JACS) pinpoints a structural instability in the myelin membranes, the "insulating tape" surrounding...

A newly discovered potential biomarker of MS may help to distinguish between people who will go on to have less severe disease and those in whom the disease will progress, researchers at Linköping...

Results from the extension period of a Phase II trial, assessing Ozanimod as a potential treatment for relapsing-remitting multiple sclerosis, showed that the drug can effectively and safely...

Results from the ORATORIO trial, exploring Ocrevus (ocrelizumab), for the treatment of primary progressive forms of MS, have shown the drug stopped disease progression for more than two years in...

Pages